Darwin Global Management, Ltd. Verve Therapeutics, Inc. Transaction History

Darwin Global Management, Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$20.92 - $39.36 $483,335 - $909,373	-23,104 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$31.94 - $54.82 $137,118 - $235,342	-4,293 Reduced 15.67%	23,104 $852,000
Q3 2021 Nov 15, 2021	SELL	$46.0 - $73.99 $3.48 Million - $5.59 Million	-75,616 Reduced 73.4%	27,397 $1.29 Million
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $3.29 Million - $6.21 Million	103,013 New	103,013 $6.21 Million

176

71.8M

115K

144K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $355M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Darwin Global Management, Ltd., based on Form 13F filings with the SEC.

Stay updated on Darwin Global Management, Ltd. with notifications on news.